Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.

Authors:
Giuseppe Luigi Banna
Giuseppe Luigi Banna
Cannizzaro Hospital
Francesco Passiglia
Francesco Passiglia
University of Palermo
Italy
Francesca Colonese
Francesca Colonese
San Raffaele Scientific Institute
Jessica Menis
Jessica Menis
University Hospital of Udine
Italy
Alfredo Addeo
Alfredo Addeo
Centro Oncologico Ematologico Subalpino
Italy
Antonio Russo
Antonio Russo
University of Palermo
Italy
Diego Luigi Cortinovis
Diego Luigi Cortinovis
San Gerardo Hospital

Crit Rev Oncol Hematol 2018 Sep 23;129:27-39. Epub 2018 Jun 23.

Medical Oncology Unit, San Gerardo Hospital, Monza, Italy.

The identification of reliable predictive biomarkers of efficacy or resistance to immune-oncology (I-O) agents is a major issue for translational research and clinical practice. However, along with PDL1 and molecular features other clinical, radiological and laboratory factors can be considered for the selection of those patients who would not be the best candidate for immune-checkpoint inhibitors (ICPIs). We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice. A thorough patient evaluation and close clinical monitoring, due to limited, early or inconclusive currently available data, should be deserved for patients with a pre-existing symptomatic chronic obstructive pulmonary disease, age >75 years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 1, a time to progression (TTP) < three months and progressive disease (PD) as the best response to the previous treatment, hepatitis or HIV-infections, high neutrophil to lymphocyte ratio (NLR), or on treatment with high-dose steroids, when the use of ICPIs is considered. Limited data are available to consider that ICPIs are safe in patients with interstitial lung disease, bronchiolitis obliterans organizing pneumonia and autommune diseases. Early evidence on steroids, vaccinations and antibiotics suggest their possible interaction with ICPIs and need to be more investigated in clinical trials. Oncogene-addicted NSCLC harboring EGFR-mutations and low tumor-infiltrating T-lymphocytes (TILs) seems not to gain benefit from I-O.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.06.016DOI Listing
September 2018
27 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter: Alfdoc2
June 29, 2018, 5:12 am EST
twitter
Twitter: Oncoblogger
June 29, 2018, 5:01 am EST
twitter
Twitter: JessicaMenis
June 28, 2018, 6:04 pm EST
twitter
Twitter: JessicaMenis
June 28, 2018, 6:04 pm EST
twitter
Twitter: Alfdoc2
June 28, 2018, 1:42 am EST
twitter
Twitter: Gbanna74
June 28, 2018, 1:18 am EST
twitter
Twitter: Gbanna74
June 28, 2018, 1:14 am EST
twitter
Twitter: Gbanna74
June 28, 2018, 1:08 am EST
twitter
Twitter: Alfdoc2
June 27, 2018, 2:52 pm EST

Publication Analysis

Top Keywords

lung cancer
8
non-small cell
8
cell lung
8
immune-checkpoint inhibitors
8
clinical practice
8
clinical
5
pre-existing symptomatic
4
autommune diseases
4
patients pre-existing
4
deserved patients
4
diseases early
4
currently data
4
pneumonia autommune
4
inconclusive currently
4
data deserved
4
pulmonary disease
4
age >75
4
obliterans organizing
4
>75 years
4
disease age
4

Similar Publications